Navigation Links
instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters
Date:11/18/2009

LOS ANGELES, Nov. 18 /PRNewswire-FirstCall/ -- instaCare Corp., (OTC Bulletin Board: ISCR), a leading distributor of life-saving prescription drugs and at-home testing diagnostics for the chronically ill, and a leading developer of patentable technologies for e-pharmacy, e-health and EMR applications, reported financial results for the third quarter period-ended September 30, 2009. Recent highlights include:

  • Revenue grew by 58% through the first three quarters in 2009 vs. the same period in 2008 as sales and orders for at-home diagnostics and medical surgical products surged
  • ISCR reports enhanced 2009 net income of $1,636,610 vs. 2008 loss of $16,775
  • Company offers cell phone EMR technologies to capitalize on Obama Administration health initiatives
  • Company announces intellectual property and patent strategies to secure its e-health and EMR technologies for Apple iPhone, Palm Pre and Verizon Windows phones

For the third quarter ended September 30, 2009 the company reported revenues of $4,491,831 vs. $3,439,271 for the same period in 2008. Through the first three quarters of 2009, instaCare reported revenues of $14,669,886 vs. $9,257,347 for the same period in 2008, a gain of 58%. The increase in revenues was due primarily to surging sales from the company's sale of at-home medical diagnostic and medical disposable products for patients with chronic diseases. The Company reported an operating profit of $161,967 during the third quarter of 2009 compared with an operating profit of $51,195 recorded during the third quarter 2008, a gain of 316%. Operating profit for the first nine months of 2009 was $1,636,610 vs. an operating loss of $16,775 for the same period in 2008. instaCare had cash, accounts, inventory and equivalents of $3,460,141 as of September 30, 2009 vs. $2,856,791 for the same period in 2008.

Keith Berman, chief financial officer of instaCare, commented, "T
'/>"/>

SOURCE instaCare Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
3. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
6. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
7. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
11. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... New data show the,investigational drug tetrabenazine maintained ... up to 80 weeks in those,patients who ... data suggest that tetrabenazine can be used ... use., "These findings demonstrate the potential benefit ...
... Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical company, ... respected scientific,journal 'Synapse'* on its Phase II NMDA ... a potential treatment for neuropathic,pain. The independent study ... with CNS 5161. , In the study reported ...
Cached Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
... and SANTA CLARA, Calif., Jan. 13 Gulf ... care facilities in,the nation, announced it will be ... ultrasound platforms from Eklin Medical Systems.,GCVS currently uses ... and Communications System) as part of the,facility,s Eklin ...
... respiratory distress, researchers say; company says product is safe ... cold remedy Vicks VapoRub may cause airway inflammation that ... study says. , Doctors at Wake Forest University started ... developed severe respiratory distress after the salve had been ...
... Interventions Incorporated into, First-of-its-Kind Study ... Jan. 13 /PRNewswire/ - MEMOTEXT announced today that ... will conduct a clinical trial on patient adherence ... technology developed by MEMOTEXT. The clinical trial, titled ...
... KENNEBUNK, Maine, Jan. 13 The new year brings ... its steadfast commitment to community programs. This month, the ... brings everyday Americans and local communities together with Tom,s ... care for families in need. Over the past four ...
... new turn. Now you can see the ... Early on Christmas morning, CNN ... "What is Telemedicine?" demonstrating how telemedicine is ... healthcare to patients at six area Walmart ...
... Synergy Connect(TM) links health plan, physicians and ... Fla., Jan. 13 Health Integrated, a ... helping people with chronic illnesses get the ... communities. Health Integrated,s groundbreaking Synergy Connect(TM) service ...
Cached Medicine News:Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 2Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 4Health News:Tom's of Maine Invites Everyone to Start the New Year by Helping Families in Need 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 3Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: